ProQR Q2 Revenue Doubles to €8.76M, Beats Consensus by 91%
PRQR sits 44% above its 52-week low of $1.33.
Summary
ProQR's Q2 revenue more than doubled to €8.76 million, nearly twice the €4.58 million consensus, while net loss narrowed to €8.73 million. The company ended the quarter with €117.1 million in cash after raising €59.2 million, providing runway for its Axiomer RNA editing pipeline. Management guided to full Phase 1 AX-0810 data at a scientific conference later in 2026, initial AX-0811 Phase 1 data by year-end, and initial biliary atresia data in H1 2027. This follows positive Phase 1 target engagement data for AX-0810 announced in June and a $55.8 million offering that closed the same month. The revenue beat and narrowed loss are incremental positives, but the stock remains a clinical-stage story where pipeline data will drive the next major move.
At the time of this announcement, PRQR was trading at $1.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $256.8M. The 52-week trading range was $1.33 to $3.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.